I think in terms of patient convenience, prefilled syringes would be the best administration option. This would totally depend on insurance coverage and affordability. Prior to these newer “biological” therapies patients did fairly well with cholinesterase inhibitors which relieve symptoms but do not address the basic pathology of antibodies...
At AAIC 2025, the Alzheimer’s Association released the first clinical practice guidelines recommending blood‑based biomarkers for Alzheimer’s pathology assessment in mild cognitive impairment or dementia. These less invasive tests aid early diagnosis and allow timely care initiation.
Source : https://pubmed.ncbi.nlm.nih.gov/40795619/
Myasthenia gravis is an autoimmune neuromuscular disease characterised by fatigable muscle weakness. The disease is caused by autoantibodies targeting components of the post-synaptic neuromuscular junction, which are identifiable in 90...
Comprehensive review detailing diagnostic and prognostic roles of autoantibodies in myasthenia gravis, including AChR, MuSK, and LRP4, with implications for disease classification, thymic status assessment, personalized management, and monitoring in generalized MG.
Fun Fact! Turns out, your brain might prefer a good night’s sleep over brain teasers. A 2025 Yale-led study found that adults who spent more time in REM and deep sleep had larger volumes in Alzheimer’s-sensitive brain regions, even 17 years later.
Could targeting REM and slow-wave sleep help delay structural brain changes tied to Alzheimer’s?
Could targeting REM and slow-wave sleep help delay structural brain changes tied to Alzheimer’s?
Source : https://pubmed.ncbi.nlm.nih.gov/40762789/
The panel concludes that, in the near future, therapeutic strategies based on the use drugs with better tolerability and potentially lower direct and indirect costs, will be necessary.
Expert panel outlines corticosteroid use in myasthenia gravis, emphasizing the need for careful dosing to avoid exacerbations and long-term side effects, while advocating for future therapies with improved tolerability.